On Monday, Exelixis Inc . (NASDAQ:EXEL) maintained its Equal Weight rating and a $23.00 stock price target according to Stephens. The decision comes as Exelixis announced a significant clinical development collaboration with Merck (NYSE:MRK) to supply KEYTRUDA for the ongoing Phase 3 STELLAR-305 trial in head and neck squamous cell carcinoma (HNSCC) and to fund pivotal trials in renal cell carcinoma (RCC).
Exelixis's collaboration with Merck, announced Today, involves the combination of KEYTRUDA with Exelixis's own cabozantinib, a therapy that has shown promise in Phase 2 trials. The data from these trials, presented at the American Society of Clinical Oncology (ASCO) meeting in 2022, supports the ongoing efforts to evaluate zanzalintinib, potentially offering a chemotherapy-free option for patients.
The biotechnology firm is also advancing the development of zanzalintinib in combination with WELIREG to solidify its position in the RCC market. This strategic move aims to build upon the success of Exelixis's CABOMETYX, which has already established a presence in the treatment landscape for RCC.
Despite the potential of zanzalintinib and the collaboration with Merck, Stephens remains cautious. The firm looks forward to observing the market performance of the zanzalintinib combination and the outcome of Exelixis's ongoing litigation under the MSN II ANDA before altering their stance on the company's stock.
The analyst noted that while the partnership with Merck is a positive step, it warrants a wait-and-see approach to assess Exelixis's market dynamics and legal challenges.
In other recent news, Exelixis, a biotechnology company, has made significant strides in its financial performance and drug development. The company's second-quarter revenues reached $637.2 million, largely driven by its leading product, cabozantinib, which contributed $437.6 million. Notably, the company's diluted net income of $0.77 per share surpassed earlier projections.
UBS initiated coverage on Exelixis stock with a Neutral rating, citing concerns about potential intellectual property risks starting from 2026 and a deceleration in the growth of Exelixis's cancer drug, Cabometyx. However, the firm also predicted that Exelixis's pipeline asset, zanzalitinib, could achieve sales of $450 million by 2028.
In analyst news, Citi reaffirmed its Buy rating on Exelixis shares, following the presentation of the final results from Exelixis's Phase 3 CABINET study. Similarly, H.C. Wainwright maintained its Buy rating and a stock price target of $29.00 on Exelixis shares, following the presentation of results from the Phase 3 CONTACT-02 trial.
In drug development, Exelixis's Phase 3 CABINET trial results showed significant improvement in progression-free survival for patients with advanced neuroendocrine tumors. The U.S. Food and Drug Administration accepted a supplemental New Drug Application for cabozantinib, a treatment for neuroendocrine tumors. Lastly, a decision on a patent dispute over Cabometyx, which will determine the drug's market exclusivity period, is imminent.
InvestingPro Insights
Exelixis Inc.'s recent collaboration with Merck aligns with its strong financial position and growth trajectory. According to InvestingPro data, the company's revenue grew by 17.48% in the last twelve months as of Q2 2024, reaching $2.01 billion. This growth is complemented by a robust gross profit margin of 96.06%, indicating efficient cost management.
InvestingPro Tips highlight that Exelixis holds more cash than debt on its balance sheet, which provides financial flexibility to fund clinical trials and potential market expansion. The company's high shareholder yield and aggressive share buyback program suggest confidence in its future prospects.
Despite Stephens' cautious stance, Exelixis's stock has shown strong performance, with a 22.8% price total return over the past year. The company is trading near its 52-week high, with its current price at 94.5% of the peak. This momentum, coupled with analysts' expectations of profitability this year, could indicate positive market sentiment towards Exelixis's strategic moves and pipeline potential.
For investors seeking a deeper understanding of Exelixis's financial health and growth prospects, InvestingPro offers 11 additional tips, providing a comprehensive analysis to inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.